Please use this identifier to cite or link to this item:
http://eprint.iitd.ac.in/handle/2074/394

Full metadata record

DC Field

Value

Language

dc.contributor.author

Guha, Sujoy K

-

dc.contributor.author

Gulshanjit Singh

-

dc.contributor.author

Ansari, Shirfuddin

-

dc.contributor.author

Sudheer Kumar

-

dc.contributor.author

Srivastava, Anil

-

dc.contributor.author

Koul, Veena

-

dc.contributor.author

Das, H C

-

dc.contributor.author

Malhotra, R L

-

dc.contributor.author

Das, S K

-

dc.date.accessioned

2005-06-27T11:07:04Z

-

dc.date.available

2005-06-27T11:07:04Z

-

dc.date.issued

1997

-

dc.identifier.citation

Contraception, 56, 245-250

en

dc.identifier.uri

http://eprint.iitd.ac.in/dspace/handle/2074/394

-

dc.description.abstract

Following up on an earlier clinical trial demonstrating the safety of an intra-vas deferens injection of a contraceptive drug named Risug, comprised of styrene maleic anhydride (SMA) in a solvent vehicle of dimethylsulphoxide (DMSO),a study to assess the contraceptive effectiveness of a specific dose (60 mg) of SMA bilaterally was planned and implemented, Male subjects and their wives with normal reproductive profiles were the volunteer subjects. The wives were not using any contraceptives. The results re-confirm the safety and show that for a period of at least 1 year, the treatment leads to azoospermia in the male and gives pregnancy protection.

en

dc.format.extent

221823 bytes

-

dc.format.mimetype

application/pdf

-

dc.language.iso

en

en

dc.subject

injectable male contraceptive

en

dc.subject

styrene maleic anhydride

en

dc.subject

pregnancy protection

en

dc.title

Phase II clinical trial of a vas deferens injectable contraceptive for the male